Researcher
Jef Rozenski
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Bioinformatics and computational biology
Affiliations
- Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 12
- Exploration of the pharmacokinetics of clindamycin and its metabolites in special patients: from bioanalysis to clinical relevanceFrom1 Oct 2021 → 30 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- An NMR facility tailored for biomedical researchFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Streamlining the route of phosphonate XNA from chemistry to applicationFrom1 Oct 2019 → 30 Sep 2023Funding: IOF - technology concept exploration, BOF - projects
- Directed evolution of bioactive compounds: Azol(in)e-containing post-translationally modified peptidesFrom1 Apr 2019 → 1 Apr 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development of a comprehensive platform for targeting redox homeostasis in Mycobacterium tuberculosis.From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Drug design strategies against newly emerging viral diseasesFrom17 Oct 2016 → 30 Oct 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development of XNA ligases as tools for synthetic biologyFrom22 Sep 2015 → 17 Oct 2019Funding: BOF - doctoral mandates, BOF - Doctoral projects
- Development of a xenozyme and an XNA ligase.From1 Oct 2014 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
- Selection of nucleic acid chemistry for therapeutic aptamer design.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project
- Oligonucleotides as biochemical and therapeutic tools.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project
Publications
1 - 10 of 82
- Assessment of in vitro antimicrobial activity of clindamycin metabolites against Staphylococcus species(2023)
Authors: Greet Van De Sijpe, Karel Allegaert, Jef Rozenski, Pieter Annaert, Stefanie Desmet
Pages: 1345 - 1347 - Assessment of in vitro antimicrobial activity of clindamycin metabolites against Staphylococcus species(2023)
Authors: Greet Van De Sijpe, Laura Armengol Álvarez, Agustos Cetin Ozbey, Karel Allegaert, Jef Rozenski, Pieter Annaert, Stefanie Desmet, Isabel Spriet
Pages: 1345 - 1347 - Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties(2023)
Authors: Elisabetta Groaz, Jef Rozenski
- Structural Basis of Cysteine Ligase MshC Inhibition by Cysteinyl-Sulfonamides(2022)
Authors: Stijn Lenders, Evgenii Osipov, Jef Rozenski, Sergei Strelkov, Arthur Van Aerschot
- Modularity of RBC hitchhiking with polymeric nanoparticles: testing the limits of non-covalent adsorption(2022)
Authors: Vincent Lenders, Xanthippi Koutsoumpou, Laura Armengol Álvarez, Jef Rozenski, Stefaan Soenen, Karel Allegaert, Jaan Toelen, Bella Manshian
- In Vivo Assembly and Expression of DNA Containing Non-canonical Bases in the Yeast Saccharomyces cerevisiae(2022)
Authors: Mikhail Abramov, Jef Rozenski, Piet Herdewyn
- Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice(2022)
Authors: Greet Van De Sijpe, Stefanie Desmet, Willem-Jan Metsemakers, Karel Allegaert, Jef Rozenski
- Overview of in-capillary enzymatic reactions using capillary electrophoresis(2022)
Authors: Jef Rozenski, Ann Van Schepdael
Pages: 57 - 73 - Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design(2021)
Authors: Weijie Gu, Sergio Martinez, Abhi Singh, Jef Rozenski, Dominique Schols, Piet Herdewyn, Kalyan Das, Steven De Jonghe
- Noncanonical DNA polymerization by aminoadenine-based siphoviruses(2021)
Authors: Jef Rozenski, Piet Herdewyn
Pages: 520 - +